# Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)

Source: https://onco.cc/trials/nct05712902/  
OnCo record `nct05712902` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sunvozertinib in non-small-cell lung cancer and small-cell lung cancer, run by Dizal Pharmaceuticals, active and no longer recruiting.

## Summary

Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6) is a phase 2 interventional study registered as NCT05712902 by Dizal Pharmaceuticals, with 104 participants enrolled, started 2021-07-19 and due to reach its primary completion in 2022-10-17. Interventions recorded: Sunvozertinib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Also known as: WU-KONG6
- Tags: ctgov-ingest
- Registry id: NCT05712902
- Phase: 2
- Setting: A Phase II, Single Arm, Multicenter Study to Evaluate Anti-tumor Activity, Safety, Tolerability and Pharmacokinetics of DZD9008 in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation
- Sponsor: Dizal Pharmaceuticals
- Enrolled: 104

## Sources

- ClinicalTrials.gov NCT05712902: https://clinicaltrials.gov/study/NCT05712902

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Sunvozertinib](https://onco.cc/drugs/sunvozertinib/)
- companies: [Dizal Pharmaceutical](https://onco.cc/companies/dizal/)
- key papers: [Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial](https://onco.cc/key-papers/paper-nct05712902-lancet-respir-med-2024/)

---
JSON: https://onco.cc/api/v1/entities/nct05712902.json